Aurinia Pharmaceuticals AUPH Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $77.71M+24.4% | $77.11M+28.8% | $73.47M+8.4% | $70.01M+22.4% | $62.47M+24.2% | ||
| $6.51M-24.1% | $8.8M+58.5% | $8.18M+35.5% | $7.12M-20.1% | $8.57M+10.6% | ||
| $71.2M+32.1% | $68.32M+25.8% | $65.29M+5.8% | $62.89M+30.3% | $53.89M+26.7% | ||
| 91.6%+5.4pp | 88.6%-2.1pp | 88.9%-2.2pp | 89.8%+5.4pp | 86.3%+1.7pp | ||
| $7.47M+30.1% | $10.9M+34.4% | $8.44M+177% | $7.43M+82.2% | $5.74M+3.5% | ||
| $22.03M+8.3% | $29.26M-21.0% | $26.18M-38.2% | $26.02M-42.1% | $20.34M-57.4% | ||
| $4.82M-0.8% | $4.86M0.0% | $4.87M-0.6% | $4.86M+0.4% | $4.86M+0.2% | ||
| $0-100% | $0-100% | $0— | $114K-89.4% | $1.53M-77.1% | ||
| -$279K+93.7% | —— | -$929K+79.7% | -$9.25M-3,288% | -$4.43M-207% | ||
| $36.28M-10.7% | $43.88M-28.7% | $43.72M-22.0% | $49.93M-15.0% | $40.62M-36.1% | ||
| $41.42M+89.6% | $33.24M+2,092% | $29.75M+153% | $20.08M+1,427% | $21.85M+265% | ||
| 53.3%+18.3pp | 43.1%+45.9pp | 40.5%+23.2pp | 28.7%+31.3pp | 35%+61.3pp | ||
| $1.01M-5.2% | $1.05M-8.6% | $1.1M-9.0% | $1.12M-6.8% | $1.07M-16.8% | ||
| $3.52M-1.5% | $3.5M-12.3% | $3.32M-22.3% | $3.19M-23.8% | $3.57M-21.1% | ||
| $43.93M+80.4% | $35.69M+2,943% | $31.96M+116% | $22.16M+1,399% | $24.35M+343% | ||
| $9.57M+852% | -$175.1M— | $411K-10.1% | $643K-14.9% | $1.01M+36.0% | ||
| $34.36M+47.2% | $210.79M+14,651% | $31.55M+120% | $21.51M+2,880% | $23.34M+317% | ||
| 44.2%+6.8pp | 273.4%+271pp | 42.9%+21.8pp | 30.7%+29.5pp | 37.4%+58.7pp | ||
| $0.25+56.3% | $1.53+15,200% | $0.23+130% | $0.16+1,500% | $0.16+329% | ||
| $0.26+52.9% | $1.60+15,900% | $0.24+140% | $0.16+1,500% | $0.17+343% | ||
| 137.6M-3.9% | 138.7M-5.1% | 136M-6.6% | 137.5M-4.6% | 143.2M-0.6% | ||
| 132.4M-4.7% | 134.4M-6.1% | 131.8M-7.9% | 134.9M-5.9% | 138.9M-3.5% | ||
| $34.07M+47.1% | $210.94M+17,976% | $31.71M+114% | $21.43M+2,889% | $23.17M+313% | ||
| -$279K+93.7% | —— | -$929K+79.7% | -$9.25M-3,288% | -$4.43M-207% | ||
| $77.71M+24.4% | $77.11M+28.8% | $73.47M+8.4% | $70.01M+22.4% | $62.47M+24.2% | ||
| $41.42M+89.6% | $33.24M+2,092% | $29.75M+153% | $20.08M+1,427% | $21.85M+265% | ||
| $46.24M+73.2% | $38.1M+1,093% | $34.61M+108% | $24.95M+649% | $26.7M+418% | ||
| $46.24M+73.2% | $38.1M+1,093% | $34.61M+108% | $24.95M+649% | $26.7M+418% | ||
| 59.5%+16.8pp | 49.4%+44.1pp | 47.1%+22.6pp | 35.6%+29.8pp | 42.7%+59.5pp | ||
| $41.42M+89.6% | $33.24M+2,092% | $29.75M+153% | $20.08M+1,427% | $21.85M+265% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aurinia Pharmaceuticals's profit margins?
- Gross margin is 89.7% and operating margin is 41.7%, with a 100.0% net margin.
- Where does Aurinia Pharmaceuticals's income statement data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.